Fatima Gasset-Rosa

Associate Director at Vividion Therapeutics

Fatima Gasset-Rosa, PhD has extensive experience in the fields of molecular biology and neurodegenerative diseases. Fatima currently holds the position of Principal Scientist at Vividion Therapeutics, Inc., where they have been working since 2020. Prior to this, they held roles at the University of California San Diego, where they served as a Senior Postdoctoral Researcher and a Postdoctoral Researcher. During their time at UC San Diego, they conducted research on protein misfolding in neurodegenerative diseases and worked on identifying biomarkers and gene targets for Huntington's disease.

Before joining UC San Diego, Fatima worked as a Graduate Researcher and PhD Candidate at the Consejo Superior de Investigaciones Científicas, where they made significant contributions to the field by discovering a prion-like protein in bacteria. Fatima also gained expertise in protein complexes imaging and single-cell protein imaging during their time there.

Additionally, Fatima has had visitor researcher positions at the Max Planck Institute for Molecular Genetics and the Université Paris Descartes, Center of Interdisciplinary Research.

Fatima Gasset-Rosa, PhD completed their education at various prestigious institutions. Fatima first received a Bachelor's degree in Molecular Genetics from the Universidad Complutense de Madrid in 2005. Later, they pursued a Master's degree in Cellular Physiology and Biology at the Université de Bordeaux I from 2003 to 2004. Finally, they obtained their Doctor of Philosophy (PhD) in Molecular Biology from the Universidad Complutense de Madrid in 2013. Recently, in 2020, they also obtained a U.S permanent resident green card.

Location

San Diego, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Vividion Therapeutics

2 followers

Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.


Industries

Employees

51-200

Links